Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication
Key Highlights
- ➤JNJ submitted an sNDA seeking FDA approval for CAPLYTA in bipolar I mania.
- ➤Two Phase 3 studies significantly reduced manic symptoms versus placebo by Day 3.
- ➤Improvement in manic symptoms remained sustained through Week 3.
- ➤Approval would become CAPLYTA’s fifth approved adult use.
- ➤CAPLYTA was well tolerated, with low discontinuation rates and consistent prior safety profile.
Expert Statements
John C. Reed, Executive Vice President, Innovative Medicine, R&D, Johnson & Johnson
“For people experiencing acute mania, rapid symptom improvement and tolerability are both critical treatment considerations,”
John C. Reed, Executive Vice President, Innovative Medicine, R&D, Johnson & Johnson
“Our Phase 3 results demonstrate the potential for CAPLYTA to address these needs, and this submission advances our ambition to provide a foundational treatment that can support patients across the evolving course of serious psychiatric disorders.”
Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication PR Newswire
* Two positive Phase 3 studies showed CAPLYTA significantly reduced manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 * As the first and only FDA-approved treatment for both bipolar I and II depression in adults as a monotherapy and adjunctive therapy, filing seeks to expand CAPLYTA for the treatment of manic or mixed episodes associated with bipolar I disorder * Approval would mark the fifth approved use of CAPLYTA in adults, building on its robust efficacy and established safety and tolerability profile across major depressive disorder, bipolar depression and schizophrenia NEW BRUNSWICK, N.J., Nov. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking the approval of CAPLYTA (lumateperone) for the treatment of manic or mixed episodes associated with bipolar I disorder in adults. The submission is supported by two pivotal Phase 3 studies in which CAPLYTA significantly reduced manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3. If approved, bipolar mania would become the fifth approved use for CAPLYTA in adults.
Get started
Create a free account to read the full story.
